[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Operazioni interne di Kiniksa Pharmaceuticals da parte del COO Eben Tessari mostrano una combinazione di acquisti e vendite eseguiti nell'ambito di un piano 10b5-1. La persona segnalante ha esercitato 6.500 opzioni gi脿 maturate al prezzo di esercizio di $8,83 il 18/08/2025, acquisendo 6.500 azioni ordinarie di Classe A. Nella stessa data la persona ha venduto 16.100 azioni a un prezzo medio ponderato di $33,77 e ulteriori 100 azioni a $34,44, riducendo la propriet脿 beneficiaria a 40.215 azioni. Il Modulo 4 precisa che le operazioni sono state effettuate ai sensi di un piano 10b5-1 stipulato il 29 aprile 2024 e che l'opzione 猫 completamente maturata ed esercitabile fino al 16/09/2029.
Las transacciones internas de Kiniksa Pharmaceuticals por parte del COO Eben Tessari muestran una combinaci贸n de compras y ventas ejecutadas bajo un plan 10b5-1. La persona informante ejerci贸 6.500 opciones adquiridas a un precio de ejercicio de $8,83 el 18/08/2025, adquiriendo 6.500 acciones ordinarias Clase A. En la misma fecha, la persona vendi贸 16.100 acciones a un precio ponderado promedio de $33,77 y otras 100 acciones a $34,44, reduciendo la titularidad beneficiaria a 40.215 acciones. El Formulario 4 indica que las operaciones se realizaron conforme a un plan 10b5-1 suscrito el 29 de abril de 2024 y que la opci贸n est谩 totalmente adquirida y puede ejercerse hasta el 16/09/2029.
Kiniksa Pharmaceuticals鞚� COO Eben Tessari鞐� 鞚橅暅 雮措秬瓯半灅電� 10b5-1 頂岆灉鞐� 霐半澕 鞁ろ枆霅� 毵れ垬鞕� 毵る弰鞚� 順柬暕鞚� 氤挫棳欷嶋媹雼�. 鞁犼碃鞚胳潃 2025雲� 8鞗� 18鞚检棎 頄夓偓臧�瓴� $8.83搿� 旮办法霌�(vested)霅� 鞓奠厴 6,500欤茧ゼ 頄夓偓頃橃棳 韥措灅鞀� A 氤错喌欤� 6,500欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 鞁犼碃鞚胳潃 臧�欷戫弶攴犼皜瓴� $33.77鞐� 16,100欤�毳�, 於旉皜搿� 100欤�毳� $34.44鞐� 毵る弰頃� 鞁れ唽鞙犾＜鞁濎垬毳� 40,215欤�搿� 臧愳唽鞁滌及鞀惦媹雼�. Form 4鞐愲姅 頃措嫻 瓯半灅霌れ澊 2024雲� 4鞗� 29鞚� 觳搓舶霅� 10b5-1 頂岆灉鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅橃柎 2029雲� 9鞗� 16鞚缄箤歆� 頄夓偓 臧�電ロ晿雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Les op茅rations d'initi茅s de Kiniksa Pharmaceuticals r茅alis茅es par le COO Eben Tessari montrent un m茅lange d'achats et de ventes ex茅cut茅s dans le cadre d'un plan 10b5-1. La personne d茅clarante a exerc茅 6 500 options acquises au prix d'exercice de 8,83 $ le 18/08/2025, acqu茅rant 6 500 actions ordinaires de classe A. La m锚me journ茅e, elle a vendu 16 100 actions 脿 un prix moyen pond茅r茅 de 33,77 $ et 100 actions suppl茅mentaires 脿 34,44 $, r茅duisant la d茅tention b茅n茅ficiaire 脿 40 215 actions. Le formulaire 4 pr茅cise que les transactions ont 茅t茅 effectu茅es conform茅ment 脿 un plan 10b5-1 ex茅cut茅 le 29 avril 2024 et que l'option est enti猫rement acquise et exer莽able jusqu'au 16/09/2029.
Interngesch盲fte von Kiniksa Pharmaceuticals durch COO Eben Tessari zeigen eine Mischung aus K盲ufen und Verk盲ufen, die im Rahmen eines 10b5-1-Plans ausgef眉hrt wurden. Die meldepflichtige Person hat am 18.08.2025 6.500 bereits erworbene Optionen ausge眉bt zum Aus眉bungspreis von $8,83 und damit 6.500 Stammaktien der Klasse A erworben. Am selben Tag verkaufte die Person 16.100 Aktien zu einem gewichteten Durchschnittspreis von $33,77 und zus盲tzlich 100 Aktien zu $34,44, wodurch das wirtschaftliche Eigentum auf 40.215 Aktien reduziert wurde. Im Formular 4 wird angegeben, dass die Transaktionen gem盲脽 einem am 29. April 2024 abgeschlossenen 10b5-1-Plan erfolgten und dass die Option vollst盲ndig erworben ist und bis zum 16.09.2029 aus眉bbar bleibt.
- Exercise of 6,500 vested options at $8.83 indicates the reporting person converted lower-cost compensation into stock
- Transactions executed under a 10b5-1 plan, providing prearranged, documented trading that reduces concerns about opportunistic timing
- Sale of 16,200 shares (16,100 at weighted-average $33.77 and 100 at $34.44) materially reduced beneficial ownership to 40,215 shares
- Significant disposition size by an executive could be viewed negatively by some investors absent further context on remaining stake or reasons for sale
Insights
TL;DR: Insider exercised options cheaply and sold a larger block at much higher market prices under a 10b5-1 plan; results are routine but notable for size.
The reporting person exercised 6,500 options at $8.83 and sold 16,200 shares at a weighted-average above $33.7, locking in substantial gross proceeds relative to exercise cost. Because the transactions were made under a documented 10b5-1 plan, timing appears pre-arranged, reducing concerns about opportunistic trading on material nonpublic information. The net effect lowered beneficial ownership to 40,215 shares, which is meaningful for an executive-level holder but not dispositive without position size or % of outstanding shares.
TL;DR: Transactions comply with 10b5-1 disclosure; the mix of exercise plus sales is governance-normal but merits tracking.
The Form 4 discloses use of a 10b5-1 plan executed April 29, 2024, which provides an affirmative defense for trading plans. The filing clearly states the option is fully vested and the sales were executed through a broker-dealer with a disclosed weighted-average sale price. From a governance perspective, documentation and transparent pricing disclosures are appropriate; no governance violations or unexplained exceptions appear in the filing.
Operazioni interne di Kiniksa Pharmaceuticals da parte del COO Eben Tessari mostrano una combinazione di acquisti e vendite eseguiti nell'ambito di un piano 10b5-1. La persona segnalante ha esercitato 6.500 opzioni gi脿 maturate al prezzo di esercizio di $8,83 il 18/08/2025, acquisendo 6.500 azioni ordinarie di Classe A. Nella stessa data la persona ha venduto 16.100 azioni a un prezzo medio ponderato di $33,77 e ulteriori 100 azioni a $34,44, riducendo la propriet脿 beneficiaria a 40.215 azioni. Il Modulo 4 precisa che le operazioni sono state effettuate ai sensi di un piano 10b5-1 stipulato il 29 aprile 2024 e che l'opzione 猫 completamente maturata ed esercitabile fino al 16/09/2029.
Las transacciones internas de Kiniksa Pharmaceuticals por parte del COO Eben Tessari muestran una combinaci贸n de compras y ventas ejecutadas bajo un plan 10b5-1. La persona informante ejerci贸 6.500 opciones adquiridas a un precio de ejercicio de $8,83 el 18/08/2025, adquiriendo 6.500 acciones ordinarias Clase A. En la misma fecha, la persona vendi贸 16.100 acciones a un precio ponderado promedio de $33,77 y otras 100 acciones a $34,44, reduciendo la titularidad beneficiaria a 40.215 acciones. El Formulario 4 indica que las operaciones se realizaron conforme a un plan 10b5-1 suscrito el 29 de abril de 2024 y que la opci贸n est谩 totalmente adquirida y puede ejercerse hasta el 16/09/2029.
Kiniksa Pharmaceuticals鞚� COO Eben Tessari鞐� 鞚橅暅 雮措秬瓯半灅電� 10b5-1 頂岆灉鞐� 霐半澕 鞁ろ枆霅� 毵れ垬鞕� 毵る弰鞚� 順柬暕鞚� 氤挫棳欷嶋媹雼�. 鞁犼碃鞚胳潃 2025雲� 8鞗� 18鞚检棎 頄夓偓臧�瓴� $8.83搿� 旮办法霌�(vested)霅� 鞓奠厴 6,500欤茧ゼ 頄夓偓頃橃棳 韥措灅鞀� A 氤错喌欤� 6,500欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 鞁犼碃鞚胳潃 臧�欷戫弶攴犼皜瓴� $33.77鞐� 16,100欤�毳�, 於旉皜搿� 100欤�毳� $34.44鞐� 毵る弰頃� 鞁れ唽鞙犾＜鞁濎垬毳� 40,215欤�搿� 臧愳唽鞁滌及鞀惦媹雼�. Form 4鞐愲姅 頃措嫻 瓯半灅霌れ澊 2024雲� 4鞗� 29鞚� 觳搓舶霅� 10b5-1 頂岆灉鞐� 霐半澕 鞚措（鞏挫鞙茧┌, 鞓奠厴鞚� 鞕勳爠頌� 旆摑霅橃柎 2029雲� 9鞗� 16鞚缄箤歆� 頄夓偓 臧�電ロ晿雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Les op茅rations d'initi茅s de Kiniksa Pharmaceuticals r茅alis茅es par le COO Eben Tessari montrent un m茅lange d'achats et de ventes ex茅cut茅s dans le cadre d'un plan 10b5-1. La personne d茅clarante a exerc茅 6 500 options acquises au prix d'exercice de 8,83 $ le 18/08/2025, acqu茅rant 6 500 actions ordinaires de classe A. La m锚me journ茅e, elle a vendu 16 100 actions 脿 un prix moyen pond茅r茅 de 33,77 $ et 100 actions suppl茅mentaires 脿 34,44 $, r茅duisant la d茅tention b茅n茅ficiaire 脿 40 215 actions. Le formulaire 4 pr茅cise que les transactions ont 茅t茅 effectu茅es conform茅ment 脿 un plan 10b5-1 ex茅cut茅 le 29 avril 2024 et que l'option est enti猫rement acquise et exer莽able jusqu'au 16/09/2029.
Interngesch盲fte von Kiniksa Pharmaceuticals durch COO Eben Tessari zeigen eine Mischung aus K盲ufen und Verk盲ufen, die im Rahmen eines 10b5-1-Plans ausgef眉hrt wurden. Die meldepflichtige Person hat am 18.08.2025 6.500 bereits erworbene Optionen ausge眉bt zum Aus眉bungspreis von $8,83 und damit 6.500 Stammaktien der Klasse A erworben. Am selben Tag verkaufte die Person 16.100 Aktien zu einem gewichteten Durchschnittspreis von $33,77 und zus盲tzlich 100 Aktien zu $34,44, wodurch das wirtschaftliche Eigentum auf 40.215 Aktien reduziert wurde. Im Formular 4 wird angegeben, dass die Transaktionen gem盲脽 einem am 29. April 2024 abgeschlossenen 10b5-1-Plan erfolgten und dass die Option vollst盲ndig erworben ist und bis zum 16.09.2029 aus眉bbar bleibt.
FAQ
What transactions did KNSA COO Eben Tessari report on Form 4?
Were the trades executed under a 10b5-1 trading plan for KNSA?
How many KNSA shares does Tessari beneficially own after these transactions?
Are the exercised options still exercisable and what are their terms?
What price range did the reported sales occur at?
